Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.

The American journal of pathology - 1 Mar 2011

Shibata Tatsuhiro, Kokubu Akiko, Miyamoto Masashi, Sasajima Yuko, Yamazaki Naoya

Abstract excerpt

Melanoma is the most deadly tumor of the skin, and systemic therapies for the advanced stage are still limited. Recent genetic analyses have revealed the molecular diversity of melanoma and potential therapeutic targets. By screening a cohort of 142 primary nonepithelial tumors, we discovered that about 10% of melanoma cases (4/39) harbored an IDH1 or IDH2 mutation. These mutations were found to coexist with BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Melanoma

Share to Mice, Nude

Share to Mutant Proteins

Share to Proto-Oncogene Proteins B-raf

Share to Reactive Oxygen Species

Source

Open in PubMed Open full text

Identifiers

PMID: 21356389
DOI: 10.1016/j.ajpath.2010.12.011
PMCID: PMC3069821

Genes

IDH1
BRAF
IDH2
KIT
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.PMID 21356389Read ↗

Clinicopathological Study of a Series of Melanomas With IDH1 Mutation.Semantic proximity Read ↗

Wild-type IDH1 inhibition enhances chemotherapy response in melanomaSemantic proximity Read ↗

Wild-type IDH1 inhibition enhances chemotherapy response in melanoma.Semantic proximity Read ↗

ALDH1A1 confers resistance to RAF/MEK inhibitors in melanoma cells by maintaining stemness phenotype and activating PI3K/AKT signaling.Semantic proximity Read ↗

ALDH2 is a novel biomarker and exerts an inhibitory effect on melanomaSemantic proximity Read ↗

JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling componentSemantic proximity Read ↗

ALDH1A1 overexpression in melanoma cells promotes tumor angiogenesis by activating the IL‑8/Notch signaling cascadeSemantic proximity Read ↗

HEDGEHOG/GLI-E2F1 axis modulates iASPP expression and function and regulates melanoma cell growthSemantic proximity Read ↗

Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations.Semantic proximity Read ↗

Recurrent co-alteration of HDGF and SETDB1 on chromosome 1q drives cutaneous melanoma progression and poor prognosis.Semantic proximity Read ↗

IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells.Semantic proximity Read ↗

hMAGEA2 Promotes Cell Growth and Tumorigenicity in MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.